Date published: 
1 May 2022
Intended audience: 
General public
Be covidsafe tile

This prescription-only oral treatment has been found to be effective in treating mild to moderate COVID-19 in adults aged 18 years of age and older, who do not require supplemental oxygen, and who are at increased risk of progressing to hospitalisation.

For more information about oral treatments for COVID-19, including Paxlovid.

Find out more about Paxlovid.

Download the PBS fact sheet

PBAC Web Outcome Statement: NIRMATRELVIR AND RITONAVIR (Paxlovid)

Consumer resources for Paxlovid on NPS MedicineWise